Latest Herceptin Stories

-- A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients(1) EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor(®) (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior...

April Flowers for redOrbit.com - Your Universe Online The Food and Drug Administration (FDA) has approved a brand new type of breast cancer medication this week that targets tumor cells while sparing healthy surrounding tissues. In U.S. women, breast cancer is the second most deadly form of cancer and is expected to kill more than 39,000 Americans this year alone, the National Cancer Institute reports. Kadcyla, from Roche, is a combination of a powerful chemotherapy drug, the...

MISSISSAUGA, ON, Dec. 10, 2012 /CNW/ - Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34 percent...

A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors. The HER family of receptors has been linked to the development of a wide variety of human cancers. HER1 inhibitors such Iressa and HER2 inhibitors such as Herceptin are commonly used in the clinic for treatment of small cell lung carcinoma and breast cancer. A recent study...

INCLINE VILLAGE, Nev., June 13, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2012, of approximately $125 million, as compared with actual royalty revenue of $122 million for the second quarter of 2011, a two percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in royalty revenues is driven by increased first quarter 2012 sales of...

A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening, various media outlets reported on Sunday. The drug, TDM-1, is manufactured by Roche, and according to Naomi Kresge and Robert Langreth of Bloomberg, it works by carrying chemotherapy directly into cancer cells while successfully avoiding healthy ones, resulting in fewer side effects than conventional treatments. According...

SAN DIEGO, March 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter and year ended December 31, 2011, and announced that Roche has submitted a Line Extension Application to the European Medicines Agency (EMA) for a subcutaneous (SC) formulation of Herceptin® (trastuzumab) to treat patients with HER2-positive breast cancer. The filing of the application triggers a $4 million milestone payment to Halozyme under the License and...

INCLINE VILLAGE, Nev., Dec. 19, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately $72 million, as compared with actual results of $76 million for the fourth quarter of 2010, a five percent decrease. Total anticipated revenue for the year ended December 31, 2011 is $361 million as compared with actual results of $345 million for the year ended December 31, 2010, a five...

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth. The finding, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium,...

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable...